Details of the Drug Formulaction

General Information of Drug Formulation (ID: F24311)

Formulation Name
Enasidenib Mesylate 100 mg tablet
Company
Celgene Corporation
Pharmaceutical Drug(s) in Formulation
Drug Name Drug ID Indication ICD 11 Status
AG-221 DMS0ZBI Acute myelogenous leukaemia 2A41 Phase 3
Pharmaceutical Excipient(s) in Formulation
Excipient Name Excipient ID PubChem CID Functional Classification
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose acetate succinate E00696 Not Available Coating agent; Solubilizing agent; Modified-release agent;Film/membrane-forming agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent